New Inhaler Significantly Reduces Asthma Attacks in Children: Landmark Trial Results

A new study offers a potential shift in how childhood asthma is managed, suggesting a combined inhaler treatment could significantly reduce attacks in children. Researchers have found that a 2-in-1 inhaler, delivering both an anti-inflammatory and a fast-acting bronchodilator, reduced asthma attacks by an average of 45% compared to the standard salbutamol inhaler currently used for symptom relief in children.

A New Approach to Childhood Asthma Relief

Asthma affects an estimated 113 million children and adolescents globally, making the search for more effective treatments a public health priority. Currently, salbutamol inhalers are the go-to for quick relief when a child experiences asthma symptoms. However, a growing body of evidence, initially established in adult studies, points to the benefits of a different approach: a combined inhaler containing budesonide (an inhaled corticosteroid) and formoterol (a fast-acting bronchodilator). This new research, published in The Lancet on September 27th, provides the first randomized controlled trial demonstrating the effectiveness of this 2-in-1 approach in children aged 5 to 15.

The study, known as CARE (Children’s Anti-inflammatory REliever), involved 360 children across New Zealand. Participants were randomly assigned to receive either the budesonide-formoterol inhaler or salbutamol when experiencing asthma symptoms over a year-long period. The results showed a rate of 0.23 asthma attacks per participant per year in the budesonide-formoterol group, compared to 0.41 attacks per participant per year in the salbutamol group. This translates to 18 fewer asthma attacks per year for every 100 children switched to the combined inhaler.

Understanding the Inhalers: Salbutamol vs. Budesonide-Formoterol

Salbutamol, a short-acting beta2-agonist, works by quickly relaxing the muscles in the airways, providing immediate relief from asthma symptoms like wheezing and shortness of breath. It’s effective for quick relief, but doesn’t address the underlying inflammation that drives asthma. Budesonide, an inhaled corticosteroid, reduces inflammation in the airways, helping to prevent asthma attacks. Formoterol, like salbutamol, is a bronchodilator, but its effects last longer. Combining budesonide and formoterol in a single inhaler offers both immediate relief and long-term inflammation control.

While the 2-in-1 inhaler is already the recommended reliever treatment for adults with asthma, children have largely continued to rely on salbutamol. This disparity prompted the CARE study, led by the Medical Research Institute of New Zealand (MRINZ) in collaboration with Imperial College London, University of Otago Wellington, Starship Children’s Hospital, and the University of Auckland. Dr. Lee Hatter, lead author of the study and Senior Clinical Research Fellow at MRINZ, emphasized the importance of addressing the “evidence gap” between adult and pediatric asthma management. ScienceDaily reports Dr. Hatter stating, “For the first time, we have demonstrated that the budesonide-formoterol 2-in-1 inhaler, used as needed for symptom relief, can significantly reduce asthma attacks in children with mild asthma.”

Safety and Generalizability: What the Study Confirmed

Crucially, the CARE study also confirmed the safety of the combined inhaler approach in children. Researchers found no significant differences in growth, lung function, or overall asthma control between the two groups. This addresses a key concern regarding the use of inhaled corticosteroids in children, as prolonged use can sometimes affect growth. The study’s pragmatic, “real-world” design – observing children as they used the inhalers in their daily lives – strengthens the generalizability of the findings to clinical practice.

Limitations and Context: The Pandemic’s Influence

The researchers acknowledge certain limitations. The trial was conducted during the COVID-19 pandemic, a period characterized by stringent public health measures and reduced circulation of respiratory viruses. This likely contributed to a lower-than-predicted rate of severe asthma attacks. Identifying asthma attacks in children can be challenging, and the lack of blinding (where neither the participants nor the researchers knew who was receiving which treatment) introduces a potential for bias. However, the study’s design aimed to minimize these biases, and the researchers believe the findings are broadly applicable.

What Does This Signify for Asthma Care?

Professor Richard Beasley, Director of MRINZ and senior author of the study, believes the findings could be “transformative” for asthma management globally. The potential to align children’s asthma guidelines with those for adults could benefit millions of children with mild-to-moderate asthma. The Global Initiative for Asthma (GINA), a leading international organization developing asthma guidelines, has already recognized the significance of the study. Professor Helen Reddel, Chair of GINA’s Science Committee, noted that the research fills a “critically important gap” in asthma management, highlighting the importance of preventing attacks to support children’s physical, social, and emotional development. New Scientist reports Professor Reddel stating that preventing asthma attacks is a “high priority for asthma care.”

Looking Ahead: Implementing the Findings

The next steps involve incorporating the CARE study’s findings into global asthma treatment strategies. This process typically involves reviews by national and international health organizations, such as the World Health Organization (WHO) and national health ministries, to update clinical guidelines. Further research, like the ongoing CARE UK study mentioned by Professor Andrew Bush of Imperial College London, will continue to refine our understanding of the optimal use of combined inhalers in children. The New Zealand Asthma and Respiratory Foundation also emphasizes the importance of this research, noting that it provides crucial evidence to support improved asthma care for children. Good News Network highlights Professor Bob Hancox’s statement that the findings will help reduce the burden of asthma for many children and families.

For parents and caregivers, this research offers a hopeful sign. While it’s essential to continue following the guidance of healthcare professionals and adhering to current asthma management plans, the potential for a more effective and preventative treatment approach is now supported by robust evidence. Anyone with concerns about their child’s asthma should consult with a qualified clinician to discuss the best course of action.